Back to MIL
Millipore Corporation Awards Flow Cytometer to Advance Cell Biology Research at Renowned Research Hospital

Millipore Corporation (NYSE: MIL), a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today awarded Dr. Mari Hashitate Dallas of St. Jude Children’s Research Hospital in Memphis, Tenn., the Millipore Guava® Flow Cytometry Award. This award recognizes her innovative approach to using flow cytometry/cell analysis to improve the outcome of umbilical cord blood transplants in pediatric patients. Dr. Dallas will receive the recently released guava easyCyte™ 8HT flow cytometry instrument to better facilitate and expedite her research.

Using this instrument will enable Dr. Dallas’ lab to more efficiently monitor the number and type of immune cells in blood samples drawn over the course of time following umbilical cord blood transplants. From this information, the lab will assess whether immune systems are properly reconstituting following transplantation and then identify the factors that improve success.

“Dr. Dallas’ submission was selected because it best represented an application of multiparametric flow cytometry that will play an important role in improving patient outcomes,” said John Sweeney, Vice President Life Science Business Unit. “Millipore is proud to support Dr. Dallas’ innovative research knowing that the flow cytometer system will help to accelerate her critical work.”

The guava easyCyte 8HT is a key cell analysis tool which allows scientists to save critical time and funds by enabling them to take control of their research without sacrificing results when compared to those generated on traditional instruments – all within their own lab. Traditional flow cytometers need a full-time technician, making them expensive to operate, but guava flow cytometers only require the individual who will run the samples. An additional benefit of this instrument is that it can handle smaller sample volumes than other flow cytometry instruments and process samples in a 96 well plate format.

“We process 200 to 300 samples at each time point in our studies,” said Dr. Dallas. “Until now, we had to send the samples to the core lab and try our best to align our research with their hours. Having a Guava flow cytometer allows us to conduct these analyses in our own lab on our own schedule,” she continued.

Dr. Dallas’ proposal was selected from more than 70 high-quality applications submitted to Millipore by research labs worldwide. Proposals were assessed for their innovative approach to using flow cytometry to address challenging research questions and represented a wide range of applications, including stem cell differentiation, cell signaling, therapeutic mechanisms of action, and the molecular basis of disease.

Dr. Mari Hashitate Dallas is a member of St. Jude Children’s Research Hospital Division of Bone Marrow Transplantation and Cellular Therapy. Her research focuses on stem cell and T-cell development, cord blood transplants, and infections and immune reconstitution after bone marrow transplant.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER TM

Research. Development. Production.

(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
Back to MIL
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki